HCG Cancer Centre, Nagpur – India
About Dr. Ajay Mehta
Dr. Ajay Mehta is among the most distinguished senior surgical oncologists. He has a profound specialisation and keen interest in the comprehensive study and advanced treatment of breast cancers. Dr. Mehta, top breast cancer surgeon in India, is recognised for his evidence-based treatment approach, meticulously tailored to meet the unique needs of each patient. His extensive career includes handling over 50,000 cases and active involvement in international multicentric clinical trials. He is committed to advancing cancer care through research, education, and patient-focused surgical excellence.
OPD Schedule Of Dr. Ajay Mehta
Consultation Fees Rs. /-
HCG NCHRI Oncology LLP, Nagpur
MON
10:00 AM - 06:00 PM
TUE
10:00 AM - 06:00 PM
WED
10:00 AM - 06:00 PM
THU
10:00 AM - 06:00 PM
FRI
10:00 AM - 06:00 PM
SAT
10:00 AM - 06:00 PM
Medical Degrees:
- MBBS
- MS (General Surgery)
- FACS (Fellow of the American College of Surgeons)
- Royal Postgraduate Medical School, London, UK
- National Cancer Institute, Tokyo, Japan
- Royal Victoria Hospital, Montreal, Canada
- City Coast Hospital, Wellington, New Zealand
Major Cancer Types Treated:
- Breast Cancer
- Other solid tumours requiring surgical intervention
- Breast Oncosurgery
- Surgical management of various malignancies
- Advanced Oncosurgical Procedures
- Specialised Breast Cancer Surgeries (e.g., Mastectomy, Lumpectomy, Axillary Dissections)
Current & Past Hospital Affiliations:
- Director & Head, Senior Surgical Oncologist, HCG Cancer Center – Nagpur (Current)
- Consultant- Fortis Hospital, Shalimar Bagh, Delhi
- Actively involved in international multicentric clinical trials (more than 70 Phase I-IV trials)
- Organised two editions of the International Cancer Congress
- Presenter at various national and international conferences
- Handled over 50,000 cancer cases.
- Pioneering work in breast cancer treatment and research.
- Authored two influential books on breast cancer.
- Significant contribution to clinical trials, advancing cancer treatment protocols.
National & International Awards:
- International Cancer Technology Transfer Award, Geneva (1990)
- International Cancer Technology Transfer Award, Geneva (1994)
- Member, Indian Medical Association (IMA)
- Member, Academy of Medical Sciences (AMS)
- Member, Indian Society of Oncology (ISOL)
- Member, Association of Surgeons of India (ASI)
- Member, Indian Breast Group
Dr. Mehta has a strong academic background with numerous contributions to medical literature.Selected Published Papers in Medical Journals:
- Effect of pranayama and mindfulness meditation on emotional distress and fatigue in adult hematological cancer patients undergoing chemotherapy. (2023)
- Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. (2022)
- Effect of Mindfulness-Based Art Therapy (MBAT) on Psychological Distress and Spiritual Wellbeing in Breast Cancer Patients Undergoing Chemotherapy. (2021)
- Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). (2021)
- Solitary Pancreatic Head Metastasis from Ductal Carcinoma of Breast: A Case Report. (2021)
- A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer. (2018)
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. (2016)
- Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT). (2015)
- HLA-DRB1 07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO. (2015)
- ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer. (2014)
- Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with metastatic breast cancer (MBC). (2014)
- ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer. (May 2014)
- Correlation between cancer phobia anxiety disorder and recurrence in breast cancer patients: Five year retrospective study in an Indian setting. (2014)
- A randomized placebo controlled study of standardized Cinnamon bark extract for prevention of breast cancer chemotherapy induced cachexia and alopecia. Conference Paper (2013)
- Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. (2012)
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Conference Paper (2012)
- LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). (2012)
- LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. (2012)
- A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. (2012)
- Breast Cancer in the New Millennium
- Changing Paradigm in the Management of Breast Cancer
For consultation fee details, you can connect with the Cancer Rounds team.The cost of treatment can vary based on the specific type of cancer, stage, recommended surgical procedure, hospital stay, and other factors. Below is an indicative table for common breast cancer surgical procedures.
Disclaimer: The above costs are estimates. They may not include costs for diagnostics, anaesthesia, post-operative care, medication, or hospital room charges beyond standard. For precise costings and treatment plans, please consult with the Cancer Rounds team.
| Surgical Procedure | Indicative Cost in INR (₹) | Indicative Cost in USD ($) |
| Lumpectomy (Breast Conserving Surgery) | ₹1,80,000 – ₹3,50,000 | $2,150 – $4,200 |
| Mastectomy (Simple/Modified Radical) | ₹2,20,000 – ₹5,00,000 | $2,650 – $6,000 |
| Sentinel Lymph Node Biopsy | ₹70,000 – ₹1,50,000 | $850 – $1,800 |
| Axillary Lymph Node Dissection | ₹1,00,000 – ₹2,00,000 | $1,200 – $2,400 |
The Cancer Rounds team is dedicated to assisting international patients seeking treatment with Dr. Ajay Mehta.Language Support:
Assistance with language interpretation services can be arranged to ensure clear communication.Visa & Travel Assistance:
Support is provided for visa applications, travel arrangements, airport transfers, and suitable accommodation booking.Pre-treatment Virtual Consultations:
Facilities for pre-treatment virtual consultations can be arranged, allowing patients to discuss their case with Dr. Mehta, share medical records, and receive an initial opinion before travelling to India.
“Dr. Ajay Mehta’s expertise in breast cancer surgery is exceptional. He explained my treatment plan with such clarity and compassion. I felt I was in the safest hands throughout my journey. I am incredibly grateful for his care.” – Mrs. S. Patil“Finding Dr. Mehta was a blessing. His approach is not just about surgery, but about holistic care. He is a true professional and a very kind human being. My family and I highly recommend him for anyone seeking a top surgical oncologist in India.” – Mr. R. Sharma“From the moment I met Dr. Mehta, I knew I could trust him. His confidence, backed by years of experience, was reassuring. He performed my surgery flawlessly, and his guidance during recovery was invaluable. Dr. mehta is a top breast cancer surgeon in India.” – Ms. A. Khan
Patient-Centred Care:
Dr. Mehta, best cancer surgeon in Nagpur, believes in a patient-first approach. His treatment strategies are guided by robust, evidence-based research and are meticulously tailored to the individual needs, circumstances, and preferences of each patient, ensuring personalised and effective care.Technology & Innovation:
He stays at the forefront of surgical advancements and incorporates innovative techniques in his practice. His active involvement in clinical trials signifies his commitment to leveraging cutting-edge research for better patient outcomes.
Frequently Asked Questions
Dr. Ajay Mehta is a senior surgical oncologist with a specialisation and keen interest in the study and surgical treatment of breast cancers. He also manages other solid tumours requiring oncosurgical intervention.
Dr. Mehta has an extensive experience of over 34 years in the field of oncosurgery.
Yes, Dr. Mehta is actively involved in international multicentric clinical trials, with more than 70 Phase I-IV trials to his credit. He has also authored books and research papers on breast cancer.
Dr. Mehta performs a range of breast cancer surgeries, including lumpectomies (breast conservation surgery), mastectomies, sentinel lymph node biopsies, and axillary lymph node dissections, tailored to the patient’s specific condition.
International patients can connect with the Cancer Rounds team for assistance with appointments, virtual consultations, travel, and accommodation for treatment with Dr. Ajay Mehta in Nagpur, India.